AbbVie and Allergan Aesthetics announced today that more than 30 abstracts, including seven podium presentations, will be presented during the upcoming TOXINS 2022 Conference, July 27-30 in New Orleans. Clinical studies, health economics, preclinical research, and real-world utilization data will highlight onabotulinumtoxinA (BOTOX® and BOTOX® Cosmetic) across approved and investigational indications.
“For more than 32 years, we have remained committed to advancing neurotoxin science to better address the unmet needs of patients across a variety of conditions and our work continues,” said Mitchell F. Brin, M.D., senior vice president, chief scientific officer, BOTOX® & Neurotoxins, AbbVie. “Our data at TOXINS reinforce not only our leadership in neurotoxin research and development, but also our commitment to provide world-class medical education to help accelerate scientific knowledge and technical skills that can help improve patient outcomes.”
At the meeting, researchers will present data on the use of onabotulinumtoxinA in chronic migraine, pediatric neurogenic detrusor overactivity, overactive bladder, cervical dystonia, and spasticity. Notable data will include an analysis from the CD-PROBE study, which evaluated the safety and efficacy of onabotulinumtoxinA in difficult-to-treat cervical dystonia postures: anterocollis and retrocollis.
Additionally, the company will share advances in aesthetic medicine, including new data on onabotulinumtoxinA in moderate to severe forehead lines, lateral canthal lines, and glabellar lines. Investigational results will also be presented from a phase 2b study of onabotulinumtoxinA in patients with masseter muscle hypertrophy.
“Our deep scientific focus continues to drive exciting innovations in aesthetic medicine,” said Darin Messina, senior vice president, global head of aesthetics R&D, AbbVie. “We look forward to presenting results from our phase 2 dose-escalation study of onabotulinumtoxinA in masseter muscle prominence, a known area of aesthetic concern for a growing number of patients.”
In addition to posters being displayed at the TOXINS 2022 conference, there will also be a virtual poster hall on the International Neurotoxin Association website here where posters will be available for viewing by conference attendees for six months after the conference.